Time to hash out a strong buy thesis again on this first day of 2018:
Those who have constantly instilled fear, uncertainty and doubt (FUD) now have a clear and loud answer:
-- the company has secured enough financial resources, not a month or weeks worthy of operating funds, but the resources which are enough to see the data of DCVax-L trial. So gone are the constant suggestions of bankruptcy, imminent default, reverse slit, and further dilution;
-- the company has come all the way into 2018: it passed planned PFS, OS analyses and entered a new phase. By doing so, it ushers in a triple insurance for the success of DCVax-L trial. So gone are the wishes of those who want the company to fail at PFS analysis dreaming pseudoprogression would not only wreak a havoc but deal a fatal blow to the the trial, those who want the company to fail at OS analysis hoping the confound effect of crossover (arm) would not only wreak a havoc but deal a final blow to the trial due to undistinguished difference between arms or a weak p value, those who have desperately wanted the company to stop the trial when the planned PFS and OS events had been reached. Instead, the trial is ongoing into a new territory just as FDA has also ushered in a new era with more favorable, flexible, caring and discrete policies toward cancer treatment developments;
-- the science behind DCVax-L is strong with numerous live examples of its wonder in treating GBM patients, and its mechanism of action (MOA) is concrete with a delicate balance no other treatments can ever never dream off as it is to be acted on human's complex brain to fight off the most heterogeneous malignant GBM tumors. So gone are the persistent nuances as if DCVax-L were designed and had been tested to be a perfect solution to the dread disease GBM (so shorts have constantly picked some imaginable bones from inside the egg's shell in order to instill FUD). Instead, in our stride to ultimately conquer the deadly GBM, DCVax-L will be proved to be the first stride in the right direction to a solution of completely defeating the ugly GBM. We know there are still some uncertainties and that is why the ongoing test, and we have endured hardships, and a long journey until today: now we know that journey will be a pause with the first successful stride in sight!
Now we hope, anticipate with new found confidence: we will achieve that first stride by meeting 1) the designed PFS requirement, and the designed OS requirement and/or 2) either the designed PFS requirement, or the designed OS requirement and/or 3) strongly favorable long-tail OS at the times of 2, 3, 4 and 5 years.
So goodbye to those who want the company to bankrupt, those who want the science to be another victim, those who have placed the short bets dreaming of making utterly excessive personal gains at the cost of delaying human's efforts to defeat cancers, whoever who have been and will be beneficial in seeing our endeavors, hardships, tears, and passions go in vain.
From our continually updated DDs, I see no hope for those fellas and their short positions in 2018 and beyond. We may see an increased trading activities with slowly steady appreciation of price.
Happy New Year, good fortune to patients, investors and anyone who cares!